Assenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Assenagon Asset Management S.A. grew its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 141.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,037,896 shares of the biopharmaceutical company's stock after purchasing an additional 1,192,489 shares during the period. Assenagon Asset Management S.A. owned approximately 0.69% of Amicus Therapeutics worth $21,765,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Amicus Therapeutics by 5.0% in the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company's stock valued at $404,308,000 after buying an additional 1,360,613 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company's stock valued at $162,713,000 after purchasing an additional 2,307,385 shares during the period. William Blair Investment Management LLC increased its position in Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock worth $128,993,000 after purchasing an additional 1,477,084 shares during the last quarter. Fiera Capital Corp raised its stake in Amicus Therapeutics by 1.1% during the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock worth $52,382,000 after purchasing an additional 58,113 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Amicus Therapeutics by 14.3% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company's stock valued at $29,964,000 after purchasing an additional 378,999 shares during the last quarter.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at $10,382,718.34. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders have sold 22,500 shares of company stock valued at $244,875. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Trading Down 0.6 %

NASDAQ FOLD traded down $0.07 during trading on Friday, hitting $11.69. The stock had a trading volume of 1,875,541 shares, compared to its average volume of 2,541,937. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The company has a market capitalization of $3.47 billion, a PE ratio of -29.97 and a beta of 0.69. The firm has a 50 day moving average price of $11.19 and a 200 day moving average price of $10.56. Amicus Therapeutics, Inc. has a twelve month low of $9.02 and a twelve month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analysts' expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The business's quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.15) earnings per share. As a group, equities research analysts forecast that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

FOLD has been the subject of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a "buy" rating and a $18.00 price target for the company. Morgan Stanley reduced their target price on Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. JPMorgan Chase & Co. lowered their price target on Amicus Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, August 16th. Bank of America boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Finally, StockNews.com raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $17.13.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.